---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

Atara Biotherapeutics

🌎 atarabio.com

Atara Biotherapeutics is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company leverages the unique biology of EBV T cells to create a robust pipeline of T-cell immunotherapies, including treatments for Epstein-Barr virus positive post-transplant lymphoproliferative disease and multiple sclerosis.

---

Atara Biotherapeutics - Latest News and Updates

• Zhongde (Ken) Wang Ph.D has left Atara Biotherapeutics, where he served as Director in Viral Vector Development, Process Science in the United States, to join Blue Lake Biotechnology as Senior Director of Process Development.
• Sergio Arce, M.D., Ph.D. has left Atara Biotherapeutics as Medical Director, Clinical Sciences to join Nkarta, Inc. as Medical Director in the United States.
• Ajay Malik is leaving Atara Biotherapeutics as Director, Medical Writing to join Harmony Biosciences as Director, Medical Writing in the United States.
• Atara Biotherapeutics is mentioned among key players in the growing TIL Cell Therapy Market projected to reach USD 4.15 billion by 2033.
• Atara Biotherapeutics has 70.9% institutional ownership and a beta of 0.32, indicating strong investor confidence and lower volatility compared to Creative Medical Technology.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.